Could This Tiny Device Help You Make an Extra $30k a Year?

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

Barton Bandy Biography and Net Worth

CEO of ReShape Lifesciences

Mr. Bandy brings extensive leadership experience in health care, specifically in the bariatric and minimally invasive surgery segments. Most recently, Mr. Bandy was President and Chief Executive officer of BroadSpot Imaging Corporation, a privately held ophthalmic imaging company, and prior to that he was President of the Wellness Division at Alphaeon Corporation. He previously spent 10 years as the senior executive leading the Inamed and Allergan Health Divisions through the launch, growth and transition of LAP-BAND®. Mr. Bandy formerly held positions of increased responsibility in sales, marketing and professional education at Ethicon Endo-Surgery and Karl Storz Endoscopy, America.

What is Barton P. Bandy's net worth?: The estimated net worth of Barton P. Bandy is at least $1,186.36 as of August 5th, 2022. Mr. Bandy owns 266 shares of ReShape Lifesciences stock worth more than $1,186 as of December 24th. This net worth evaluation does not reflect any other assets that Mr. Bandy may own. Learn More about Barton P. Bandy's net worth.
How do I contact Barton P. Bandy?: The corporate mailing address for Mr. Bandy and other ReShape Lifesciences executives is 1001 Calle Amanecer, San Clemente CA, 92673. ReShape Lifesciences can also be reached via phone at (949) 429-6680 and via email at [email protected]. Learn More on Barton P. Bandy's contact information.
Has Barton P. Bandy been buying or selling shares of ReShape Lifesciences?: Barton P. Bandy has not been actively trading shares of ReShape Lifesciences during the last ninety days. Most recently, Barton P. Bandy sold 4 shares of the business's stock in a transaction on Friday, August 5th. The shares were sold at an average price of $1,363.00, for a transaction totalling $5,452.00. Following the completion of the sale, the chief executive officer now directly owns 266 shares of the company's stock, valued at $362,558. Learn More on Barton P. Bandy's trading history.
Who are ReShape Lifesciences' active insiders?: ReShape Lifesciences' insider roster includes Barton Bandy (CEO), Dan Gladney (Director), and Thomas Stankovich (CFO). Learn More on ReShape Lifesciences' active insiders.

Barton P. Bandy Insider Trading History at ReShape Lifesciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/5/2022	Sell	4	$1,363.00	$5,452.00	266
7/1/2022	Sell	3	$1,595.00	$4,785.00	270
6/1/2022	Sell	3	$2,755.00	$8,265.00	274
4/1/2022	Sell	3	$3,277.00	$9,831.00	282
1/31/2022	Sell	2	$3,538.00	$7,076.00
1/4/2022	Sell	2	$5,191.00	$10,382.00
12/2/2021	Sell	4	$5,307.00	$21,228.00
11/2/2021	Sell	4	$7,801.00	$31,204.00
10/1/2021	Sell	4	$8,033.00	$32,132.00
9/10/2021	Sell	101	$8,381.00	$846,481.00	331

Barton P. Bandy Buying and Selling Activity at ReShape Lifesciences

ReShape Lifesciences Company Overview

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

Today's Range

Now: $4.46

$4.37

$4.46

50 Day Range

MA: $5.38

$4.26

$6.62

2 Week Range

Now: $4.46

$4.09

$29.00

Volume

3,522 shs

Average Volume

94,104 shs

Market Capitalization

$3.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41